Literature DB >> 25187517

Activation of LTBP3 gene by a long noncoding RNA (lncRNA) MALAT1 transcript in mesenchymal stem cells from multiple myeloma.

Bingzong Li1, Ping Chen1, Jing Qu2, Lei Shi2, Wenyue Zhuang3, Jinxiang Fu1, Jun Li1, Xiaohui Zhang1, Yu Sun1, Wenzhuo Zhuang4.   

Abstract

Long noncoding RNAs (lncRNAs) are emerging as important regulatory molecules in tumor suppressor and oncogenic pathways. However, the magnitude of the contribution of lncRNA expression to normal human tissues and cancers has not been investigated in a comprehensive manner. Here we explored the biology of the lncRNA MALAT1 and considered the potential significance in mesenchymal stem cells from myeloma patients. By using assays such as RNA interference, luciferase, chromatin immunoprecipitation, and RNA immunoprecipitation, we showed that in mesenchymal stem cells MALAT1 promoted the activation effect of the key transcription factor Sp1 on LTBP3 promoter by modulating recruitment of Sp1 to the LTBP3 gene that regulated the bioavailability of TGF-β in particular. Our data suggested that lncRNA MALAT1 directly interacted with Sp1 and LTBP3 promoter to increase expression of LTBP3 gene. The specificity and efficiency of activation were ensured by the formation of a stable complex between MALAT1 and the LTBP3 promoter, direct interaction of MALAT1 with Sp1, and recruitment of Sp1 to the promoter. In this study, we showed that the mechanism of transcriptional activation of LTBP3 promoter depended on MALAT1 initiated from neighboring gene LTBP3 and involved both the direct interaction of the Sp1 and promoter-specific activation. Our knowledge of the role of MALAT1 in cellular transformation is pointing toward its potential use as a biomarker and a target for novel therapeutic approaches in multiple myeloma.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Biomarker; Mesenchymal Stem Cells (MSCs); Multiple Myeloma; RNA; Transcription

Mesh:

Substances:

Year:  2014        PMID: 25187517      PMCID: PMC4200285          DOI: 10.1074/jbc.M114.572693

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes.

Authors:  Keiko Tano; Rie Mizuno; Tomoko Okada; Randeep Rakwal; Junko Shibato; Yoshinori Masuo; Kenichi Ijiri; Nobuyoshi Akimitsu
Journal:  FEBS Lett       Date:  2010-10-13       Impact factor: 4.124

2.  A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression.

Authors:  Delphine Bernard; Kannanganattu V Prasanth; Vidisha Tripathi; Sabrina Colasse; Tetsuya Nakamura; Zhenyu Xuan; Michael Q Zhang; Frédéric Sedel; Laurent Jourdren; Fanny Coulpier; Antoine Triller; David L Spector; Alain Bessis
Journal:  EMBO J       Date:  2010-08-20       Impact factor: 11.598

3.  Control of RNA processing by a large non-coding RNA over-expressed in carcinomas.

Authors:  Rui Lin; Manami Roychowdhury-Saha; Chris Black; Andrew T Watt; Eric G Marcusson; Susan M Freier; Thomas S Edgington
Journal:  FEBS Lett       Date:  2011-01-23       Impact factor: 4.124

4.  A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response.

Authors:  Maite Huarte; Mitchell Guttman; David Feldser; Manuel Garber; Magdalena J Koziol; Daniela Kenzelmann-Broz; Ahmad M Khalil; Or Zuk; Ido Amit; Michal Rabani; Laura D Attardi; Aviv Regev; Eric S Lander; Tyler Jacks; John L Rinn
Journal:  Cell       Date:  2010-08-06       Impact factor: 41.582

Review 5.  TGF-β-related mechanisms of bone destruction in multiple myeloma.

Authors:  Toshio Matsumoto; Masahiro Abe
Journal:  Bone       Date:  2010-06-01       Impact factor: 4.398

6.  Impairment in immunomodulatory function of mesenchymal stem cells from multiple myeloma patients.

Authors:  Bingzong Li; Jinxing Fu; Ping Chen; Wenzhuo Zhuang
Journal:  Arch Med Res       Date:  2010-11       Impact factor: 2.235

7.  Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene.

Authors:  Y Kotake; T Nakagawa; K Kitagawa; S Suzuki; N Liu; M Kitagawa; Y Xiong
Journal:  Oncogene       Date:  2010-12-13       Impact factor: 9.867

8.  Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma.

Authors:  Bingzong Li; Mingxia Shi; Jing Li; Hongbing Zhang; Bin Chen; Lei Chen; Weibo Gao; Nicola Giuliani; Robert Chunhua Zhao
Journal:  Stem Cells Dev       Date:  2007-12       Impact factor: 3.272

9.  Activation of p53 by MEG3 non-coding RNA.

Authors:  Yunli Zhou; Ying Zhong; Yingying Wang; Xun Zhang; Dalia L Batista; Roger Gejman; Peter J Ansell; Jing Zhao; Catherine Weng; Anne Klibanski
Journal:  J Biol Chem       Date:  2007-06-13       Impact factor: 5.157

10.  Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis.

Authors:  Rajnish A Gupta; Nilay Shah; Kevin C Wang; Jeewon Kim; Hugo M Horlings; David J Wong; Miao-Chih Tsai; Tiffany Hung; Pedram Argani; John L Rinn; Yulei Wang; Pius Brzoska; Benjamin Kong; Rui Li; Robert B West; Marc J van de Vijver; Saraswati Sukumar; Howard Y Chang
Journal:  Nature       Date:  2010-04-15       Impact factor: 49.962

View more
  41 in total

1.  Multi-level regulation of PKCδI alternative splicing by lithium chloride.

Authors:  Deena Bader; Rekha S Patel; Ashley Lui; Chetna Thawani; Rea Rupani; Gitanjali Vidyarthi; Niketa A Patel
Journal:  Mol Cell Biol       Date:  2020-12-07       Impact factor: 4.272

Review 2.  The long noncoding RNA Malat1: Its physiological and pathophysiological functions.

Authors:  Xuejing Zhang; Milton H Hamblin; Ke-Jie Yin
Journal:  RNA Biol       Date:  2017-10-06       Impact factor: 4.652

3.  Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression.

Authors:  Li Chen; Ning Hu; Chao Wang; Hongmian Zhao; Yueli Gu
Journal:  Cell Cycle       Date:  2018-01-29       Impact factor: 4.534

4.  MALAT1 functions as a competing endogenous RNA to mediate Rac1 expression by sequestering miR-101b in liver fibrosis.

Authors:  Fujun Yu; Zhongqiu Lu; Jing Cai; Kate Huang; Bicheng Chen; Guojun Li; Peihong Dong; Jianjian Zheng
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  HBx-related long non-coding RNA MALAT1 promotes cell metastasis via up-regulating LTBP3 in hepatocellular carcinoma.

Authors:  Zhouhua Hou; Xuwen Xu; Xiaoyu Fu; Shuhui Tao; Jiebin Zhou; Shuiping Liu; Deming Tan
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

6.  Sp1 in Astrocyte Is Important for Neurite Outgrowth and Synaptogenesis.

Authors:  Chia-Yang Hung; Tsung-I Hsu; Jian-Ying Chuang; Tsung-Ping Su; Wen-Chang Chang; Jan-Jong Hung
Journal:  Mol Neurobiol       Date:  2019-07-18       Impact factor: 5.590

Review 7.  Perspectives of long non-coding RNAs in cancer.

Authors:  Arunagiri Kuha Deva Magendhra Rao; Thangarajan Rajkumar; Samson Mani
Journal:  Mol Biol Rep       Date:  2017-04-08       Impact factor: 2.316

8.  Novel insight into MALAT-1 in cancer: Therapeutic targets and clinical applications.

Authors:  Danyang Ren; Huiying Li; Renqiu Li; Jianming Sun; Pin Guo; Huiyun Han; Yuehuang Yang; Jun Li
Journal:  Oncol Lett       Date:  2016-01-22       Impact factor: 2.967

9.  Downregulation of lncRNA-MALAT1 Affects Proliferation and the Expression of Stemness Markers in Glioma Stem Cell Line SHG139S.

Authors:  Yong Han; Liang Zhou; Tingfeng Wu; Yulun Huang; Zhe Cheng; Xuetao Li; Ting Sun; Youxin Zhou; Ziwei Du
Journal:  Cell Mol Neurobiol       Date:  2015-12-09       Impact factor: 5.046

10.  lncRNA ST3GAL6‑AS1 promotes invasion by inhibiting hnRNPA2B1‑mediated ST3GAL6 expression in multiple myeloma.

Authors:  Ying Shen; Yuandong Feng; Fangmei Li; Yachun Jia; Yue Peng; Wanhong Zhao; Jinsong Hu; Aili He
Journal:  Int J Oncol       Date:  2021-03-02       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.